Literature DB >> 24468804

The evidence for the use of nutritional support in liver disease.

Ronald L Koretz1.   

Abstract

PURPOSE OF REVIEW: Although there is a well established association between malnutrition and poorer clinical outcomes in patients with liver disease, that fact alone does not prove that improving the malnutrition will improve outcome. The best way to determine if nutritional interventions are effective is to compare them to untreated control groups in well designed and executed randomized clinical trials. RECENT
FINDINGS: A recent systematic review assessed 37 trials that compared parenteral nutrition, enteral nutrition, or nutritional supplements to no nutritional therapy in patients with a variety of liver diseases. Since the publication of that review, an additional three trials have become available. Whereas all but one of the trials did have methodologic shortcomings that may have allowed the introduction of bias (which usually results in an overestimation of benefit), the trials failed to show much, if any, benefit. In fact, the single trial at low risk of bias found that more deaths occurred in the recipients of the supplements.
SUMMARY: Although malnutrition may be associated with a poor outcome, the current best evidence indicates that the provision of adjunctive nutritional support (parenteral or enteral nutrition, or nutritional supplements) to patients with a variety of liver diseases (alcoholic hepatitis, cirrhosis, hepatocellular carcinoma, liver surgery, liver transplantation, obstructive jaundice, hepatitis C antiviral treatment) does not improve clinical outcomes.

Entities:  

Mesh:

Year:  2014        PMID: 24468804     DOI: 10.1097/MOG.0000000000000049

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  8 in total

1.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

Review 2.  Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.

Authors:  Jaividhya Dasarathy; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Alcohol Clin Exp Res       Date:  2017-07-11       Impact factor: 3.455

3.  Intensive Enteral Nutrition in Alcoholic Hepatitis: More Food for Thought.

Authors:  Puneet Puri; Mark Thursz
Journal:  Gastroenterology       Date:  2016-02-26       Impact factor: 22.682

4.  Systematic review of peri-operative nutritional support for patients undergoing hepatobiliary surgery.

Authors:  Yin Liu; Xiaoyan Xue
Journal:  Hepatobiliary Surg Nutr       Date:  2015-10       Impact factor: 7.293

5.  Hepatorenal syndrome: outcome of response to therapy and predictors of survival.

Authors:  Jan Heidemann; Christoph Bartels; Christoph Berssenbrügge; Hartmut Schmidt; Tobias Meister
Journal:  Gastroenterol Res Pract       Date:  2015-04-23       Impact factor: 2.260

6.  Clinical significance of preoperative nutritional parameter and patient outcomes after pancreatectomy: A retrospective study at two academic institute.

Authors:  Atsushi Nanashima; Masahide Hiyoshi; Naoya Imamura; Koichi Yano; Takeomi Hamada; Rouko Hamada; Kenzo Nagatomo; Makoto Ikenoue; Shuichi Tobinaga; Takeshi Nagayasu
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2019-05-31

7.  The Chinese Herb Jianpijiedu Contributes to the Regulation of OATP1B2 and ABCC2 in a Rat Model of Orthotopic Transplantation Liver Cancer Pretreated with Food Restriction and Diarrhea.

Authors:  Baoguo Sun; Yan Chen; Ting Xiang; Lei Zhang; Zexiong Chen; Shijun Zhang; Houming Zhou; Shuqing Chen
Journal:  Biomed Res Int       Date:  2015-11-17       Impact factor: 3.411

Review 8.  A Comprehensive Review of Bioelectrical Impedance Analysis and Other Methods in the Assessment of Nutritional Status in Patients with Liver Cirrhosis.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  Gastroenterol Res Pract       Date:  2017-08-13       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.